Featured Publications
Cytomegalovirus-related Complications and Management in Facial Vascularized Composite Allotransplantation: An International Multicenter Retrospective Cohort Study
Kauke-Navarro M, Panayi AC, Formica R, Marty F, Parikh N, Foroutanjazi S, Safi AF, Mardini S, Razonable RR, Morelon E, Gelb B, Rodriguez E, Lassus P, Pomahac B. Cytomegalovirus-related Complications and Management in Facial Vascularized Composite Allotransplantation: An International Multicenter Retrospective Cohort Study. Transplantation 2022, 106: 2031-2043. PMID: 35389381, DOI: 10.1097/tp.0000000000004132.Peer-Reviewed Original ResearchConceptsRetrospective cohort studyAntiviral prophylaxisCohort studyComposite allotransplantationInternational multicenter retrospective cohort studyMulticenter retrospective cohort studyCMV-related complicationsFirst year posttransplantHigh-risk transplantsMore rejection episodesHigh-risk groupFacial Vascularized Composite AllotransplantationAllograft-related complicationsVascularized Composite AllotransplantationPaucity of dataAllograft lossCMV diseaseCMV viremiaCytomegalovirus serostatusR serostatusRejection episodesCMV infectionPrompt treatmentActive surveillancePatients
2023
Novel Strategies in Transplantation: Genetic Engineering and Vascularized Composite Allotransplantation
Kauke-Navarro M, Noel O, Knoedler L, Knoedler S, Panayi A, Stoegner V, Huelsboemer L, Pomahac B. Novel Strategies in Transplantation: Genetic Engineering and Vascularized Composite Allotransplantation. Journal Of Surgical Research 2023, 291: 176-186. PMID: 37429217, DOI: 10.1016/j.jss.2023.04.028.Peer-Reviewed Original ResearchConceptsImmunosuppressive regimensAllograft rejectionComposite allotransplantationDonor-derived immune cellsDonor-derived T lymphocytesRecipient-derived T cellsPotent immunosuppressive regimensToxic immunosuppressive regimensSolid organ transplantationAntigen-presenting cellsSystemic side effectsVascularized Composite AllotransplantationCD40 knockoutChronic rejectionRejection episodesSystemic immunosuppressionMost patientsImmunomodulatory strategiesTolerance inductionImmune cellsOrgan transplantationT cellsT lymphocytesSide effectsClinical successCellular activation pathways and interaction networks in vascularized composite allotransplantation
Knoedler L, Knoedler S, Panayi A, Lee C, Sadigh S, Huelsboemer L, Stoegner V, Schroeter A, Kern B, Mookerjee V, Lian C, Tullius S, Murphy G, Pomahac B, Kauke-Navarro M. Cellular activation pathways and interaction networks in vascularized composite allotransplantation. Frontiers In Immunology 2023, 14: 1179355. PMID: 37266446, PMCID: PMC10230044, DOI: 10.3389/fimmu.2023.1179355.Peer-Reviewed Original ResearchConceptsVascularized Composite AllotransplantationComposite allotransplantationRecipient-derived lymphocytesTreatment of patientsCellular activation pathwaysMultidrug immunosuppressionVCA graftsVCA patientsVCA rejectionGraft rejectionDevastating injuriesClinical managementNovel therapiesReconstructive surgeryLimb lossRejection responseFacial disfigurementAllotransplantationPatientsGraftActivation pathwayTissue cellsDifferent cell typesTissue typesCell typesTolerance Induction in Vascularized Composite Allotransplantation—A Brief Review of Preclinical Models
Huelsboemer L, Kauke-Navarro M, Reuter S, Stoegner V, Feldmann J, Hirsch T, Kueckelhaus M, Dermietzel A. Tolerance Induction in Vascularized Composite Allotransplantation—A Brief Review of Preclinical Models. Transplant International 2023, 36: 10955. PMID: 36846605, PMCID: PMC9946984, DOI: 10.3389/ti.2023.10955.Peer-Reviewed Original ResearchConceptsTolerance inductionLong-term effectsAnimal modelsImmune systemDonor-specific toleranceLong-term outcomesRecipient's immune systemPreclinical animal modelsNovel therapeutic strategiesPre-clinical studiesVascularized Composite AllotransplantationChronic rejectionImmunosuppressive protocolsTransplant recipientsAllograft rejectionOrgan dysfunctionPreclinical modelsComposite allograftsTherapeutic strategiesComposite allotransplantationClinical practiceIS protocolClinical translationInductionReview article
2021
Donor and Recipient Matching in Facial Vascularized Composite Allotransplantation: A Closer Look at the Donor Pool
Kauke M, Haug V, Obed D, Diehm Y, Tchiloemba B, Safi AF, Pomahac B. Donor and Recipient Matching in Facial Vascularized Composite Allotransplantation: A Closer Look at the Donor Pool. Plastic & Reconstructive Surgery 2021, 148: 194-202. PMID: 34181616, DOI: 10.1097/prs.0000000000008094.Peer-Reviewed Original ResearchConceptsDonor poolHepatitis CUnited NetworkPotential donorsEpstein-Barr virus seropositivityCytomegalovirus-seropositive donorsUnderrepresented patient groupsOrgan Sharing databaseFacial Vascularized Composite AllotransplantationHigh-risk characteristicsVascularized Composite AllotransplantationActual wait timesAllotransplant patientsSeronegative patientsSeropositive donorsMost patientsAllotransplant recipientsPatient characteristicsRecipient matchingSharing databasePositive donorsPatient groupVirus seropositivityOrgan SharingOrgan donors
2020
Mucosa and Rejection in Facial Vascularized Composite Allotransplantation: A Systematic Review.
Kauke M, Safi AF, Zhegibe A, Haug V, Kollar B, Nelms L, Palmer WJ, Tchiloemba B, Lian CG, Murphy GF, Pomahac B. Mucosa and Rejection in Facial Vascularized Composite Allotransplantation: A Systematic Review. Transplantation 2020, 104: 2616-2624. PMID: 32053572, DOI: 10.1097/tp.0000000000003171.Peer-Reviewed Original ResearchConceptsMucosal rejectionSystematic reviewRejection gradeMucosal biopsiesPatient managementComposite allotransplantationDiagnosis of rejectionFunction of patientsFacial Vascularized Composite AllotransplantationMeta-Analyses (PRISMA) guidelinesMEDLINE/PubMedPreferred Reporting ItemsVascularized Composite AllotransplantationPosttransplant periodBiopsy gradeSkin rejectionMucosa biopsiesAllograft skinAnimal studiesReporting ItemsBiopsyRejection processFacial allotransplantsMucosaTarget tissues
2019
MMP3 Is a Non-invasive Biomarker of Rejection in Skin-Bearing Vascularized Composite Allotransplantation: A Multicenter Validation Study
Kollar B, Uffing A, Borges TJ, Shubin AV, Aoyama BT, Dagot C, Haug V, Kauke M, Safi AF, Talbot SG, Morelon E, Dakpe S, Pomahac B, Riella LV. MMP3 Is a Non-invasive Biomarker of Rejection in Skin-Bearing Vascularized Composite Allotransplantation: A Multicenter Validation Study. Frontiers In Immunology 2019, 10: 2771. PMID: 31849957, PMCID: PMC6897344, DOI: 10.3389/fimmu.2019.02771.Peer-Reviewed Original ResearchConceptsMatrix metalloproteinase-3MMP3 levelsNon-invasive biomarkersTransplant recipientsAcute rejectionHealthy controlsComposite allotransplantationRejection stateCandidate non-invasive biomarkersUpper extremity transplant recipientsSerum samplesAntibody-mediated rejectionKidney transplant recipientsSeverity of rejectionPre-transplant levelsAutoimmune skin diseaseLongitudinal serum samplesSkin disease patientsVascularized Composite AllotransplantationMulticenter validation studyFace transplant recipientsLarger validation studiesClinical VCARejection episodesVCA patients